Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Acute Myeloid Leukemia (AML)

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    455 result(s) found for: Acute Myeloid Leukemia (AML). Displaying page 4 of 23.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2015-001611-12 Sponsor Protocol Number: 56022473AML2002 Start Date*: 2015-07-03
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized Phase 2/3 Study of DACOGEN® (Decitabine) Plus JNJ-56022473 (Anti-CD123) Versus DACOGEN (Decitabine) Alone in Patients with AML who are not Candidates for Intensive Chemotherapy
    Medical condition: Acute Myeloid Leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) DE (Completed) GB (Completed) SE (Completed) PL (Completed) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004761-17 Sponsor Protocol Number: SG033-0003 Start Date*: 2008-05-14
    Sponsor Name:Seattle Genetics, Inc.
    Full Title: A Phase IIB, Randomized, Double-Blinded, Placebo-Controlled Study of Low Dose Cytarabine and Lintuzumab Compared to Low Dose Cytarabine and Placebo in Patients 60 Years of Age and Older with Previo...
    Medical condition: acute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) HU (Prematurely Ended) AT (Completed) PL (Prematurely Ended) BG (Prematurely Ended) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2015-002892-30 Sponsor Protocol Number: 1315.2 Start Date*: 2016-04-14
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: An open-label, Phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858 in combination with decitabine in patients with acute myel...
    Medical condition: patients with acute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-002864-36 Sponsor Protocol Number: PKRPC001 Start Date*: 2021-11-04
    Sponsor Name:Priothera S.A.S.
    Full Title: A prospective randomized, double-blind, placebo-controlled, multi-center phase IIb study to evaluate the efficacy and safety of mocravimod in acute myeloid leukemia (AML) patients undergoing alloge...
    Medical condition: Patients undergoing allogeneic hematopoietic stem cell transplant (HSCT) for acute myeloid leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10018651 Graft versus host disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000400-99 Sponsor Protocol Number: PLMA34 Start Date*: 2014-09-15
    Sponsor Name:Radboud university medical center
    Full Title: 10-day decitabine, fludarabine and 2 Gray TBI as conditioning strategy for poor and very poor risk AML in CR1
    Medical condition: Acute myeloid leukemia AML
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10001941 AML LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003210-40 Sponsor Protocol Number: IMGN632-0801 Start Date*: 2019-02-27
    Sponsor Name:IMMUNOGEN, INC.
    Full Title: A Phase 1/2, Multi-center, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients with CD123- positive Acute Myeloid Leukemia and Other CD123 positive Hematologic Malignancies
    Medical condition: CD123 positive Acute Myeloid Leukemia and other CD123 positive hematologic malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005241-20 Sponsor Protocol Number: F14512IN102G1 Start Date*: 2013-02-18
    Sponsor Name:Pierre Fabre Medicament
    Full Title: Phase I-II study of F14512 in combination with cytarabine in patients 60 years old and older with acute myeloid leukemia.
    Medical condition: The scope of this study is the treatment of patient acute myeloid leukaemia.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) IT (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-002702-21 Sponsor Protocol Number: UKH062014 Start Date*: 2015-07-14
    Sponsor Name:Martin-Luther-Universität Halle- Wittenberg
    Full Title: A double- blind, placebo controlled, randomized, multicenter, Phase II study to assess the efficacy of BL-8040 addition to consolidation therapy in AML patients
    Medical condition: consolidation therapy in acute myeloid leukemia in first complete remission
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Temporarily Halted)
    Trial results: View results
    EudraCT Number: 2022-001279-15 Sponsor Protocol Number: KB-LANRA-1001 Start Date*: 2022-11-22
    Sponsor Name:Kronos Bio, Inc.
    Full Title: A Phase 1b/2 study of the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the selective SYK inhibitor lanraplenib (LANRA) in combination with the FLT3 inhibitor gilteritinib...
    Medical condition: Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003969-10 Sponsor Protocol Number: MB-105 Start Date*: 2018-06-08
    Sponsor Name:Moleculin Biotech, Inc.
    Full Title: Phase 1/2 Study of Liposomal Annamycin for the Treatment of Subjects with Acute Myeloid Leukemia (AML) that is Refractory to or Relapsed after Induction Therapy
    Medical condition: Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000404-92 Sponsor Protocol Number: HOVON 92 AML Start Date*: 2008-09-12
    Sponsor Name:HOVON Foundation
    Full Title: Randomized study to assess the added value of Laromustine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously untreated acute myeloid leukemia...
    Medical condition: AML according to WHO classification (excluding acute promyelocytic leukaemia) or refractory anemia with excess of blasts (RAEB) and IPSS score ≥1.5 or therapy-related AML/RAEB or biphenotypic le...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000886 Acute myeloid leukemia LLT
    9.1 10054593 Refractory anemia with excess blasts in transformation LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-018539-16 Sponsor Protocol Number: KKS-134 Start Date*: 2010-09-28
    Sponsor Name:Philipps-Universität Marburg
    Full Title: A double-blind, placebo-controlled, randomized, multi-center phase II trial to assess the efficacy of Sorafenib-maintenance therapy in Flt3-ITD positive AML in complete hematological remission afte...
    Medical condition: Flt3-ITD positive AML
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004427-38 Sponsor Protocol Number: 0001A3-300-GL Start Date*: 2009-01-28
    Sponsor Name:Antisoma Research Ltd.
    Full Title: Phase 3 Open-Label Randomized Study of Amonafide L-Malate in Combination with Cytarabine Compared to Daunorubicin in Combination with Cytarabine in Patients with Secondary Acute Myeloid Leukemia (AML)
    Medical condition: secondary acute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Ongoing) AT (Prematurely Ended) HU (Prematurely Ended) EE (Prematurely Ended) CZ (Completed) GB (Prematurely Ended) ES (Prematurely Ended) BE (Completed) IT (Prematurely Ended) GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-001086-41 Sponsor Protocol Number: UKM10_0014 Start Date*: 2012-02-28
    Sponsor Name:University Hospital of Muenster
    Full Title: A randomized, placebo-controlled, multi-center phase I/II trial to assess the safety and efficacy of nintedanib (BIBF 1120) added to low-dose cytarabine in elderly patients with AML unfit for an in...
    Medical condition: untreated acute myeloid leukemia patients unfit for an intensive treatment
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-003863-23 Sponsor Protocol Number: TUD-MOSAIC-075 Start Date*: 2020-07-03
    Sponsor Name:Technische Universität Dresden
    Full Title: Midostaurin + Gemtuzumab Ozogamicin combination in first-line standard therapy for acute myeloid leukemia
    Medical condition: Patients with newly diagnosed acute myeloid leukemia (AML) fit for intensive curative treatment displaying a cytogenetic aberration or fusion transcript in the core-binding factor (CBF) genes or FL...
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-018980-41 Sponsor Protocol Number: Pediatric_Relapsed_AML2010/01 Start Date*: 2013-10-15
    Sponsor Name:German Society of Pediatric Hematology and Oncology gGmbH (GPOH gGmbH)
    Full Title: International randomized phase III study on the treatment of children and adolescents with refractory or relapsed acute myeloid leukemia
    Medical condition: Pediatric relapsed or refractory AML
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) HU (Completed) DK (Prematurely Ended) CZ (Prematurely Ended) NL (Ongoing) SE (Prematurely Ended) IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005493-10 Sponsor Protocol Number: MB-106 Start Date*: 2022-03-22
    Sponsor Name:Moleculin Biotech, Inc.
    Full Title: Phase 1/2 Study of Liposomal Annamycin in Combination with Cytarabine for the Treatment of Subjects with Acute Myeloid Leukemia (AML).
    Medical condition: Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-003191-12 Sponsor Protocol Number: TUD-2DAUNO-058 Start Date*: 2014-01-31
    Sponsor Name:Technische Universität Dresden
    Full Title: Randomized comparison between two dose levels of daunorubicin and between one versus two cycles of in-duction therapy for adult patients with acute myeloid leukemia ≤65 years
    Medical condition: Newly diagnosed AML other than acute promyelocytic leukemia (APL) according to WHO criteria, i.e. bone marrow aspirate or biopsy must contain ≥20% blasts of all nucleated cells or differential bloo...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    21.1 100000004864 10066353 Treatment related acute myeloid leukemia LLT
    21.0 100000004864 10000887 Acute myeloid leukemia in remission LLT
    21.0 100000004864 10054294 Acute myeloid leukemia (in remission) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2005-001721-29 Sponsor Protocol Number: SPD758-216 Start Date*: 2005-12-05
    Sponsor Name:SGX Pharmaceuticals, Inc.
    Full Title: An Open-Label, Single-Arm, Multi-Center, Phase II/III study of Troxatyl (Troxacitabine) Administered by Continuous Infusion in Patients with Acute Myeloid Leukemia (AML) in second salvage
    Medical condition: Acute Myeloid Leukemia (AML)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003025-28 Sponsor Protocol Number: TUD-RELAX1-070 Start Date*: Information not available in EudraCT
    Sponsor Name:Technische Universität Dresden
    Full Title: Phase-I/II trial for relapsed or refractory AML patients combining cytarabine and mitoxantrone with venetoclax
    Medical condition: Patients 18-75 years with acute myeloid leukaemia (AML) at first or second relapse after intensive chemotherapy including allogeneic stem cell transplantation or primary refractory to standard indu...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 06:59:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA